HPV DNA test launched by Metropolis Healthcare and Roche Diagnostics
This test detects 14 high-risk HPV types in a single tube and is a clinically validated, FDA-approved, and WHO-prequalified solution
Metropolis Healthcare announced its collaboration with Roche Diagnostics India and Neighbouring Markets to introduce the self-sampling human papillomavirus (HPV) DNA test for cervical cancer screening. The launch of this test aims to expand access to cervical cancer screening across India by addressing social and economic barriers and making early detection more convenient for women, including those in tier 2, tier 3, and tier 4 towns.
The HPV DNA test is recognised by the World Health Organization (WHO) as a first-choice screening method for cervical cancer prevention. This test detects 14 high-risk HPV types in a single tube and is a clinically validated, FDA-approved, and WHO-prequalified solution. It ensures reliable and accurate diagnosis, paving the way for early intervention and better outcomes. It can address barriers such as stigma, discomfort, and limited access to healthcare facilities.
Commenting on the launch, Surendran Chemmenkotil, Chief Executive Officer, Metropolis Healthcare, said, “Cervical cancer remains a major health challenge for Indian women, despite being preventable through early screening and vaccination. By introducing advanced screening tools like the HPV DNA test, in collaboration with Roche Diagnostics India, we aim to expand access to early detection across the country.”
“Considering that as per a 2020 NHFS survey, only about 1.9 per cent women in India are currently being screened, it is clear that more needs to be done to make cervical cancer screening accessible across India. Our cobas HPV DNA test provides women with a solution that allows them to overcome the potential embarrassment and discomfort that some may feel about undergoing the cervical cancer screening process.” said Rishubh Gupta, Managing Director, Roche Diagnostics India and Neighbouring Markets
Dr Kirti Chadha, Chief Scientific and Innovation Officer and Senior Oncopathologist, Metropolis Healthcare, said: “Cervical cancer’s slow progression offers a critical window for early detection, yet lack of awareness and timely screening remain significant barriers. The introduction of self-sampling high-risk HPV DNA testing is a major step forward, making screening more accessible and patient-friendly. “
- Advertisement -